MarginsXMarginsX
Home › Markets › Health Care › RLYB

Rallybio Corporation (RLYB)

RLYB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.43
-1.88% on the day
Market cap
$86.4M
Micro cap
Revenue · 2025
$858K
+34.9% on 2024
Net income · 2025
-$9.0M
-1046.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/0001628280-26-018261-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRLYB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001739410
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$858K
Net income-$9.0M
Operating income-$33.1M
Net margin-1046.4%
Operating margin-3853.6%
Revenue growth+34.9%
Cash$31.4M
Total assets$62.3M
P/E (computed)Net income was not positive
P/S (computed)100.7×

Warning signs

Cash runway
Cash-flow positive
$90.7M cash at September 30, 2026
Share count, 1 year
+2.0%
2025-10-31 to 2026-10-20 · +14.0% over 3 years
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
$4.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$90.7M cash; operating cash flow $7.7M a quarter.Report 2026-09-30
Shares outstanding5,383,937 (2026-10-20); 42,243,774 a year earlier; 37,793,705 three years earlier. 1y figure adjusted for split (1-for-8 overall); 3y figure adjusted for split (1-for-8 overall).Cover page 2026-10-20
Reverse splits, 3 years1; latest 1-for-8 on 2026-02-06Source 2026-02-06
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Hartford, Connecticut, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $4.2M, sold $4K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$2.7M-$2.3M$90.7MNo debt tags$434K10-Q 2026-10-27
Q2 2026
2026-06-30
$0$43.7M$45.9M$92.8MNo debt tags$646K10-Q 2026-08-06
Q1 2026
2026-03-31
$212K-$8.3M-$8.0M$41.3MNo debt tags$858K10-Q 2026-05-13
Q4 2025
2025-12-31
$222K-$5.9M-$4.7M$31.4MNo debt tags$858K10-K 2026-03-16
Q3 2025
2025-09-30
$212K$16.0M-$6.5M$32.1MNo debt tags$674K10-Q 2026-10-27
Q2 2025
2025-06-30
$212K-$9.7M-$8.4M$9.4MNo debt tags$761K10-Q 2026-08-06
Q1 2025
2025-03-31
$212K-$9.4M-$10.2M$14.8MNo debt tags$848K10-Q 2026-05-13
Q4 2024
2024-12-31
$38K-$11.0M-$9.9M$13.9MNo debt tags$636K10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-15
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-10-27
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-01-02

Source: SEC EDGAR submissions feed, 314 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.2%
1 month-6.0%
3 months-7.3%
Year to date+186.4%
1 year+199.5%
From 52-week high-8.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NKTXNkarta Inc.$1.21+1.68%$86.8M
GNLXGenelux Corporation$1.92+2.95%$86.9M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
PLYXPolaryx Therapeutics Inc.$1.67-6.99%$83.2M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier